FIELD: medicine; pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and medicine, namely to treating COVID-19. Disclosed is use of 1-[2-(1-methylimidazol-4-yl)-ethyl]perhydroazine-2,6-dione or a pharmaceutically acceptable salt thereof for the treatment and/or prevention of mild COVID-19 disease, and symptoms.
EFFECT: use of the invention enables the effective treatment of mild COVID-19.
16 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF GLUTARIMIDE DERIVATIVE FOR THERAPY OF DISEASES ASSOCIATED WITH ABERRANT ACTIVITY OF INTERLEUKIN-6 | 2020 |
|
RU2774928C2 |
| NEW CRYSTAL FORM OF 1-[2-(1-METHYLIMIDAZOL-4-YL)ETHYL]PERHYDROAZINE-2,6-DIONE AND ITS PHARMACEUTICAL USE | 2022 |
|
RU2809992C1 |
| PHARMACEUTICAL COMPOSITION 1-[2-(1-METHYLIMIDAZOL-4-YL)-ETHYL]PERHYDROAZINE-2,6-DIONE FOR THERAPY OF RESPIRATORY DISEASES | 2021 |
|
RU2823588C2 |
| USE OF 1-(2-(1N-IMIDAZOL-4-YL)ETHYL)PIPERIDINE-2,6-DIONE FOR TREATING COUGH CAUSED BY VIRAL INFECTIONS | 2022 |
|
RU2819722C2 |
| 2-(IMIDAZOL-4-YL)-ETHANAMIDE OF PENTANEDIOIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING COVID-19 AND SYMPTOMS THEREOF | 2021 |
|
RU2824607C2 |
| USE OF A DERIVATIVE GLUTARIMIDE TO OVERCOME RESISTANCE TO STEROIDS AND THERAPY OF DISEASES ASSOCIATED WITH ABERRANT SIGNALING OF INTERFERON GAMMA | 2018 |
|
RU2712281C1 |
| NEW CRYSTAL FORM OF 1-(2-(1H-IMIDAZOL-4-YL)ETHYL)PIPERIDINE-2,6-DIONE AND ITS PHARMACEUTICAL APPLICATION | 2022 |
|
RU2812541C1 |
| PEPTIDE FOR TREATING CYTOKINE STORM SYNDROME | 2021 |
|
RU2834279C1 |
| NOVEL 2-(IMIDAZOL-4-YL)-ETHANAMIDE PENTANEDIOIC-1,5 ACID COMPOSITIONS FOR TREATING AND PREVENTING VIRAL DISEASES | 2020 |
|
RU2746692C1 |
| PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF VIRAL DISEASES | 2021 |
|
RU2780252C1 |
